BioCentury | Feb 6, 2021
Product Development

Picking vaccine strategies that could hold up to COVID variants

...UB-612 from United Biomedical Inc.’s COVAXX unit, which is in the process of merging with United Neuroscience...
BioCentury | Nov 25, 2020
Product Development

Nov. 25 Quick Takes: FDA approves Y-mAbs’ Danyelza; plus NIH’s ACTT-4; COVAXX, Urovant, SomaLogic, Eluminex and Liquidia

...$2.8 billion. The United Biomedical Inc. subsidiary, which is in the process of merging with United Neuroscience...
BioCentury | Nov 7, 2020
Emerging Company Profile

Vaxxinity: supplanting mAbs with vaccines for chronic disease

...the merger of its two predecessor entities, United Neuroscience...
...the same vaccine platform for different purposes. United Neuroscience...
...enough early clinical data in Alzheimer’s, via United Neuroscience...
BioCentury | Aug 2, 2019
Company News

Aug. 1 Management tracks: R&D chief leaving Adaptimmune; plus Frontier Medicines builds out team and more

...hiring Ajay Verma as SVP, head of experimental medicine and neurology. He was CMO at United Neuroscience...
BioCentury | Jan 18, 2019
Clinical News

United Neuroscience's vaccine leads to 96% response rate in Chinese Phase IIa for Alzheimer's

...medical journals. The double-blind Chinese study enrolled about 43 patients to receive UB-311 or placebo. United Neuroscience...
...β amyloid designed to induce high B cell specific responses while avoiding T cell inflammation. United Neuroscience...
...disease Endpoint: Safety and immunogenicity Status: Phase IIa data Milestone: NA Sandi Wong UBITh Amyloid-beta (UB-311) United Biomedical Inc. United Neuroscience Ltd. Beta...
BioCentury | Dec 22, 2018
Company News

Management tracks: United Neuroscience, Zymergen

...Neurodegenerative diseases company United Neuroscience Ltd. (Dublin, Ireland) hired Peter Powchik as its first EVP of R&D, effective...
BioCentury | May 4, 2018
Emerging Company Profile

Needling out Alzheimer’s

...of patients in a Phase II study of AN-1792 developed meningoencephalitis. CMO Ajay Verma said United Neuroscience’s...
...complex manufacturing process. “The cost of goods is easier with vaccines,” he said. Last year, United Neuroscience...
...“United Neuroscience is well funded past the completion of the UB-311 Phase IIa trial.” COMPANY PROFILE United Neuroscience Ltd....
BioCentury | Apr 13, 2018
Company News

UT Southwestern to evaluate United Neuroscience's Endobody vaccine candidates

...Southwestern Medical Center (Dallas, Texas) will evaluate vaccine candidates based on the Endobody platform from United Neuroscience Ltd....
...postmortem tissue samples and preclinical models of neurodegenerative disease. The companies declined to provide details. United Neuroscience Ltd....
...of Texas Southwestern Medical Center, Dallas, Texas Business: Neurology Jaime De Leon University of Texas Southwestern Medical Center United Neuroscience Ltd....
BioCentury | Mar 30, 2018
Company News

United Neuroscience, CNRS to target alpha synuclein to treat PD

...CNRS will characterize the candidates and evaluate their ability to treat PD and other synucleinopathies. United Neuroscience Ltd....
...Recherche Scientifique (CNRS), Paris, France Business: Neurology Shannon Lehnbeuter Centre National de la Recherche Scientifique (CNRS) Alpha synuclein (SNCA) United Neuroscience Ltd....
BioCentury | Jun 2, 2017
Clinical News

United Neuroscience reports Phase I data for AD vaccine UB-311

...trial of UB-311 to treat early to mild AD are expected in mid-2018. In 2014, United Neuroscience...
...Hauppauge, N.Y.) and received exclusive, worldwide rights to UB-311. United Biomedical Inc. , Hauppauge, N.Y. United Neuroscience...
...Endpoint: Safety and immunogenicity Status: Phase I data Milestone: Phase II data (mid-2018) Alicia Parker UB-311 United Biomedical Inc. United Neuroscience Ltd. Beta...
Items per page:
1 - 10 of 11
BioCentury | Feb 6, 2021
Product Development

Picking vaccine strategies that could hold up to COVID variants

...UB-612 from United Biomedical Inc.’s COVAXX unit, which is in the process of merging with United Neuroscience...
BioCentury | Nov 25, 2020
Product Development

Nov. 25 Quick Takes: FDA approves Y-mAbs’ Danyelza; plus NIH’s ACTT-4; COVAXX, Urovant, SomaLogic, Eluminex and Liquidia

...$2.8 billion. The United Biomedical Inc. subsidiary, which is in the process of merging with United Neuroscience...
BioCentury | Nov 7, 2020
Emerging Company Profile

Vaxxinity: supplanting mAbs with vaccines for chronic disease

...the merger of its two predecessor entities, United Neuroscience...
...the same vaccine platform for different purposes. United Neuroscience...
...enough early clinical data in Alzheimer’s, via United Neuroscience...
BioCentury | Aug 2, 2019
Company News

Aug. 1 Management tracks: R&D chief leaving Adaptimmune; plus Frontier Medicines builds out team and more

...hiring Ajay Verma as SVP, head of experimental medicine and neurology. He was CMO at United Neuroscience...
BioCentury | Jan 18, 2019
Clinical News

United Neuroscience's vaccine leads to 96% response rate in Chinese Phase IIa for Alzheimer's

...medical journals. The double-blind Chinese study enrolled about 43 patients to receive UB-311 or placebo. United Neuroscience...
...β amyloid designed to induce high B cell specific responses while avoiding T cell inflammation. United Neuroscience...
...disease Endpoint: Safety and immunogenicity Status: Phase IIa data Milestone: NA Sandi Wong UBITh Amyloid-beta (UB-311) United Biomedical Inc. United Neuroscience Ltd. Beta...
BioCentury | Dec 22, 2018
Company News

Management tracks: United Neuroscience, Zymergen

...Neurodegenerative diseases company United Neuroscience Ltd. (Dublin, Ireland) hired Peter Powchik as its first EVP of R&D, effective...
BioCentury | May 4, 2018
Emerging Company Profile

Needling out Alzheimer’s

...of patients in a Phase II study of AN-1792 developed meningoencephalitis. CMO Ajay Verma said United Neuroscience’s...
...complex manufacturing process. “The cost of goods is easier with vaccines,” he said. Last year, United Neuroscience...
...“United Neuroscience is well funded past the completion of the UB-311 Phase IIa trial.” COMPANY PROFILE United Neuroscience Ltd....
BioCentury | Apr 13, 2018
Company News

UT Southwestern to evaluate United Neuroscience's Endobody vaccine candidates

...Southwestern Medical Center (Dallas, Texas) will evaluate vaccine candidates based on the Endobody platform from United Neuroscience Ltd....
...postmortem tissue samples and preclinical models of neurodegenerative disease. The companies declined to provide details. United Neuroscience Ltd....
...of Texas Southwestern Medical Center, Dallas, Texas Business: Neurology Jaime De Leon University of Texas Southwestern Medical Center United Neuroscience Ltd....
BioCentury | Mar 30, 2018
Company News

United Neuroscience, CNRS to target alpha synuclein to treat PD

...CNRS will characterize the candidates and evaluate their ability to treat PD and other synucleinopathies. United Neuroscience Ltd....
...Recherche Scientifique (CNRS), Paris, France Business: Neurology Shannon Lehnbeuter Centre National de la Recherche Scientifique (CNRS) Alpha synuclein (SNCA) United Neuroscience Ltd....
BioCentury | Jun 2, 2017
Clinical News

United Neuroscience reports Phase I data for AD vaccine UB-311

...trial of UB-311 to treat early to mild AD are expected in mid-2018. In 2014, United Neuroscience...
...Hauppauge, N.Y.) and received exclusive, worldwide rights to UB-311. United Biomedical Inc. , Hauppauge, N.Y. United Neuroscience...
...Endpoint: Safety and immunogenicity Status: Phase I data Milestone: Phase II data (mid-2018) Alicia Parker UB-311 United Biomedical Inc. United Neuroscience Ltd. Beta...
Items per page:
1 - 10 of 11